comparemela.com

Page 6 - Sara Hurvitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Identifying Patients Suitable for Adjuvant Neratinib

Identifying Patients Suitable for Adjuvant Neratinib
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

How Does Response to Neoadjuvant Therapy Affect Prognosis and Inform Adjuvant Selection?

Dr Tripathy provides clinical insight on how he assesses HER2+ eBC patient response to neoadjuvant therapy, discusses the typical prognosis for those who do or do not have residual disease, and touches on how he might approach adjuvant treatment selection for each.

Adjuvant Therapy Options in HER2+ eBC and Clinical Data on the PH Regimen

Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting.

Tech Moves: Open-source software company Expanso names CEO; Highspot adds exec; and more

Tech Moves: Open-source software company Expanso names CEO; Highspot adds exec; and more
geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.

Dr Sara Hurvitz receives 2023 ESMO Breast Cancer Award

Dr. Sara A. Hurvitz is the recipient of the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Award for her remarkable contributions to breast cancer clinical and laboratory-based research.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.